checkAd

     101  0 Kommentare Knight Therapeutics Inc. Celebrates its First Decade of Success - Seite 2

    “I am incredibly proud of what we have accomplished to date and I am excited about the future achievements that we will deliver to all of our stakeholders. None of this would be possible without the fantastic team that we have in place across all our countries. Their unwavering commitment and dedication to serving patients have been instrumental in shaping Knight as the partner of choice for Canada and Latin America,” said Samira Sakhia, President and Chief Executive Officer.

    About Knight Therapeutics Inc.

    Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca.

    Forward-Looking Statements

    This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2022, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

    Seite 2 von 3


    Aktuelle Themen


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Knight Therapeutics Inc. Celebrates its First Decade of Success - Seite 2 MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion …

    Schreibe Deinen Kommentar

    Disclaimer